Posts by month
October 2020
Dose dense chemotherapy in Luminal B breast cancers
Interview with Lucia Del Mastro, MD, Department of Internal Medicine and Medical Specialties, School of Medicine, University of Genova, Italy. Q. Your recent paper in the European Journal of Cancer…
A silver lining: Could changes forced by the pandemic point to better ways to conduct our clinical trials?
Pragmatic adjustments to trial protocols were seen to be essential during the Covid-19 pandemic to avoid trials being abandoned or delayed. Most changes involved reducing the requirements for travelling to…
Their fingers on the button: why neglecting radiation therapists is no longer an option
Can you be sure that the person who positions you on the radiotherapy table and delivers your prescribed dose has received the necessary training and education? Europe’s radiation therapist profession…
SPCC task force raises awareness of malnutrition and cachexia in cancer patients
Key points The presence of cachexia is being recognised to have a negative impact on surgery and immune therapy. In the absence of pharmacological therapies multimodal treatments, such as nutrition…
Four steps to eliminating HPV-related cancers: a call for action
A new report underlines that vaccination, screening, treatment and public awareness, provide the cornerstone for eliminating cancers linked to the human papillomavirus (HPV) in Europe. The report was published by…
These COVID days
‘Tackling cancer in interesting times’ was the theme of my first Editorial for Cancer World. I wrote that at the start of February this year, at a time when Europe…
Delivering cancer care during the pandemic: lessons from the ‘first wave’
As the COVID-19 pandemic shows signs of an autumn resurgence, we look at how the ‘first wave’ impacted on the delivery of cancer care, and review responses to the Cancer…
Smoke without fire? Should cancer of unknown primary be treated as a separate disease?
Pathology-based treatment approaches are not effective in many cases of CUP due to its elusive biology. We examine the arguments for switching to a tissue-agnostic approach that targets actionable mutations…
Cancer deaths fall, health disparities persist, cancer research affected, reports AACR
The American Association for Cancer Research (AACR) annual Cancer Progress Report for 2020, published 23 September, portrays a mixed picture. On a positive note, the report features advances in cancer…
Metastatic prostate cancer: cabazitaxel shows quality of life benefits over both abiraterone and enzalutamide
In addition to previously reported survival benefits, the taxane cabazitaxel improved quality of life in patients with advanced metastatic prostate cancer compared to the androgen signalling targeted inhibitors abiraterone and…